Skip to Content
주식/증권 ➡️ 중립

Biogen’s Alzheimer’s Drug Fell Short of Targets. Why the Stock Is Rising Anyway.

요약

Biogen’s diranersen showed ‘robust reductions’ in key biomarkers during a Phase 2 trial, the biotech said.